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Multiple Determinants of Specific Modes of Prescription Opioid
Diversion
Theodore J. Cicero, Steven P. Kurtz, Hilary L. Surratt, Gladys E. Ibanez, Matthew S. Ellis,
Maria A. Levi-Minzi, and James A. Inciardi
Abstract
Numerous national surveys and surveillance programs have shown a substantial rise in the abuse
of prescription opioids over the past 15 years. Accessibility of these drugs to non-patients is the
result of their unlawful channeling from legal sources to the illicit marketplace (diversion).
Empirical data on diversion remain absent from the literature. This paper examines abusers’
sources of diverted drugs from two large studies: 1) a national sample of opioid treatment clients
(N=1983), and 2) a South Florida study targeting diverse populations of opioid abusers (N=782).
The most common sources of diverted medications were dealers, sharing/trading, legitimate
medical practice (e.g., unknowing medical providers), illegitimate medical practice (e.g., pill
mills), and theft, in that order. Sources varied by users’ age, gender, ethnicity, risk-aversiveness,
primary opioid of abuse, injection drug use, physical health, drug dependence, and either access to
health insurance or relative financial wealth. Implications for prescription drug control policy are
discussed.
Introduction
Numerous national surveys, prescription drug abuse surveillance programs and other
federally supported monitoring systems have shown a substantial rise in the abuse/misuse of
prescription opioids over the past 15 years (Bergman & Dahl-Puustinen, 1989;
Blumenschein, 1997; Borsack, 1986–1987; Cooper, Czechowicz, Petersen, & Molinari,
1992; Inciardi, Surratt, Stivers, & Cicero, 2009; Manchikanti, Fellows, Ailinani, & Pampati,
2010; McCabe, Teter, & Boyd, 2004; Monheit, 2010; Ruetsch, 2010; Simoni-Wastila &
Tompkins, 2001; Strassels, 2009; Wilford, Finch, Czechowicz, & Warren, 1994; Zacny et
al., 2003). The accessibility of these drugs to non-patients is the result of their unlawful
channeling from legal sources to the illicit marketplace, which is commonly referred to as
“drug diversion”. The Drug Enforcement Administration (DEA) has estimated that
prescription drug diversion is a $25 billion-a-year industry (The U.S. General Accountability
Office [GAO], 2003).
It is generally believed that the major mechanisms of diversion include: the illegal sale and
recycling of prescriptions by physicians and pharmacists; “doctor shopping” by individuals
who visit numerous physicians to obtain multiple prescriptions; theft, forgery, or alteration
of prescriptions by patients; robberies and thefts from manufacturers, distributors, and
pharmacies; and thefts of institutional drug supplies (Weathermon, 1999). Furthermore,
there is growing evidence that the diversion of significant amounts of prescription analgesics
and benzodiazepines occurs through residential burglaries (aNational Association of Drug
Diversion Investigators [NADDI], 2005a b c d) as well as cross-border smuggling at both
retail and wholesale levels (Inciardi, 2005; Inciardi & Surratt, 2005). In addition, recent
research by the current investigators, and others in the prescription drug abuse field, has
documented diversion through such other channels as: pain clinics (Rigg, March, & Inciardi,
2010); “shorting” (under counting) and pilferage by pharmacists and pharmacy employees;
medicine cabinet thefts by cleaning and repair personnel in residential settings; theft of
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guests’ medications by hotel housekeeping staff; and Medicare and Medicaid fraud by
patients, pharmacies, and street dealers (Inciardi & Surratt, 2005; Leiderman, 2006). Finally,
a number of observers consider the Internet to be a significant source for illegal purchases of
prescription drugs (The National Center on Addiction and Substance Abuse [CASA], 2004),
although this is highly controversial (Inciardi et al., 2010).
Empirical data on the scope and magnitude of diversion are largely unavailable and remain
absent from the literature. In fact, at two recent meetings sponsored by the College on
Problems of Drug Dependence focusing on the “Impact of Drug Formulation on Abuse
Liability, Safety, and Regulatory Decisions” and “Risk Management and Post-Marketing
Surveillance of CNS Drugs,” the proceedings of which have been published (Dart, 2009;
Dasgupta & Schnoll, 2009; Johanson et al., 2009; Liederman, 2009; McCormick, 2006;
Sapienza, 2006), representatives from government regulatory agencies, the pharmaceutical
industry, and the research community agreed that: a) there are no data on the magnitude of
particular types of diversion; b) there are no systematic data on how the massive quantities
of abused prescription drugs are reaching the streets; and, c) there are no empirical data that
might be used for making regulatory decisions and for developing prescription drug
prevention and risk management plans. In addition, although a number of studies have
addressed the patterns of prescription drug abuse and diversion among health care
professionals (Hollinger & Dabney, 2002; Inciardi et al., 2009; Trinkoff, Storr, & Wall,
1999; Trinkoff, Zhou, Storr, & Soeken, 2000; Weir, 2000), very little is known about the
magnitude and mechanisms of diversion among other types of prescription drug misusers
(e.g., street addicts, methadone clients and so forth) or whether the type of drug being
misused influences the means of diversion (e.g., OxyContin® vs. methadone).
Within this context, this paper examines the nature, scope, and magnitude of prescription
drug diversion in two different but complementary study samples: First, self-administered,
brief paper surveys of a very large sample (N=1,983) of opioid dependent patients entering
primarily (>70%) private treatment programs around the country; and, second, a more
traditional, focused, interview-based study of diverse samples of prescription opioid abusers
in South Florida (N=782) using standardized instruments.
Methods
Survey of Key Informants’ Patients (SKIP)
The nation-wide survey, termed the Survey of Key Informants’ Patients (SKIP), is a key
element of the post-marketing surveillance system known as Researched Abuse, Diversion
and Addiction-Related Surveillance (RADARS®). The detailed methodology can be found
elsewhere (see, Cicero, Surratt, & Inciardi, 2007; Cicero, Ellis, Paradis, & Ortbal, 2010), but
briefly, the SKIP program consists of nearly 100 treatment centers, balanced geographically
with a good representation of large urban, suburban and rural treatment centers. Each of the
treatment centers were asked to recruit as many patients/clients as possible who had a
diagnosis of prescription opioid analgesic abuse or dependence using the Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Inclusion criteria were very
broad: first, subjects had to be 18 years of age or older; and second, as mentioned above,
they needed to meet DSM-IV criteria for substance abuse, with their primary drug a
prescription opioid (i.e., not heroin). Overall, 85% of the patients approached by the
treatment counselors completed surveys and submitted them.
The patients were asked to complete a detailed survey instrument, covering demographics,
licit and illicit patterns of drug use, diagnostic criteria for alcohol and opioid abuse or
dependence (DSM-IV criteria; [e.g., loss of control of drinking or drugging, disruption of
everyday activities as a consequence of use, family and friend complaints about abuse,
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withdrawal, craving, and so forth]), chronic non-withdrawal bodily pain and its intensity
(scale of 1–10 with 1 being none and 10 the worst possible pain), and, whether they were
currently being treated for a psychiatric condition. Participants received a $25 gift card to
Wal-Mart or other designated store for their participation.
Completed survey instruments were identified solely by a unique case number and were
mailed by the participant directly to Washington University School of Medicine in St. Louis.
The treatment specialists did not see the detailed responses of their patients/clients.
The protocol was approved by the Washington University Institutional Review Board (IRB).
South Florida Study
Participants
To be eligible for the study, individuals needed to be 18 years of age or older and report the
misuse of at least one prescription drug five or more times in the previous 90 days. From
this population, only those who chose a prescription opioid as their most frequently misused
drug were included for the analyses (n=782).
Measures
The Global Appraisal of Individual Needs (GAIN); (Dennis, Titus, White, Unsicker, &
Hodgkins, 2002) was the primary instrumentation for the study. The GAIN (Dennis et al.,
2002) has eight core sections (background, substance use, physical health, risk behaviors,
mental health, environment, legal and vocational), with each containing questions on the
recency of problems, breadth of symptoms, and recent prevalence in days or times, as well
as lifetime service utilization. The items are combined into over 100 scales and subscales
that can be used for DSMIV based diagnoses. Psychometric studies have found Cronbach’s
alphas between .9 and .8; all have alphas over .7. Similarly, behavior questions have
demonstrated test-retest correlations of .7 to .8. For this study, questions were added to the
GAIN: 1) to increase the number of prescription drug categories so as to separately
distinguish the major prescription drugs of abuse; and, 2) to assess mechanisms of access to
the diverted drugs. To assist study respondents in making accurate reports of their
prescription drug abuse histories, the investigators developed a comprehensive pictorial
guide depicting brand name and generic drugs on the market by dosage size.
Participants were assessed on several demographic characteristics including age, gender, and
race/ethnicity (African-American, Hispanic/Latino, White, Other). They were asked
whether, in the past 90 days, they had any form of health insurance, whether they
experienced severe pain, and whether physical health problems limited their ability to
undertake vigorous activities; response choices were dichotomous (yes/no).
The assessment instrument captured a complete illicit and prescription (non-prescribed) drug
use history in number of days each substance was used in the past 90 days, and also whether
the participant injected endorsed drugs in the past 90 days. Prescription drugs included
fentanyl, hydrocodone, hydromorphone, immediate (IR) and extended (ER) release
oxycodone, morphine, and methadone, as well as alprazolam, diazepam and clonazepam.
Participants were also asked what method they used to obtain each diverted prescription
drug they misused in the past 90 days. Diversion methods included script doctor (“pill”
mill), doctor shopping, regular doctor, pharmacist, theft, dealer, sharing or trading, family,
transport from another country, or internet purchase; response choices were dichotomous
(yes/no).
Cicero et al. Page 3
J Drug Issues. Author manuscript; available in PMC 2012 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Procedures
Recruitment
A variety of purposive sampling strategies were used to locate study participants. Print
media advertisements and the posting or manual distribution of cards and flyers were largely
used, but other techniques such as chain-referrals with incentives, presentations at
community organizations, and referrals from methadone clinic and drug treatment center
staffs were also used. The study was conducted in the investigators’ research field offices or
in treatment centers located in Broward, Lee, Miami-Dade, and Palm Beach Counties.
Screening
All participants were screened for eligibility before they were asked to participate in a single
standardized face-to-face interview. Participants called the study phone number and were
screened over the phone by research staff. If eligible, interested street drug users were then
scheduled for an interview at a research field office. Eligible methadone clients were
scheduled to be interviewed for an interview at the methadone clinic that they regularly
attended. Eligible public and private-pay treatment clients were screened by treatment center
staff and scheduled to be interviewed at the treatment facility.
Interviewing
Before administering the computer-assisted face-to-face interviews, each participant was re-
screened to ensure eligibility, followed by informed consent. Interviews were conducted in
private offices and lasted 1 ½ to 2 hours. Participants received a $30 monetary incentive for
their participation. All study protocols and instruments were reviewed and approved by the
University of Delaware’s Institutional Review Board.
Data Analyses
Data from the SKIP self-administered surveys and the interview questionnaires from the
South Florida study were analyzed using Predictive Analytics Software (PASW, formerly
SPSS) version 18. Descriptive statistics were calculated to describe both samples in terms of
demographics, physical health, substance use and dependence, and primary prescription
opioid of abuse. Primary prescription opioid was determined by the specific opioid class
(hydrocodone, IR oxycodone, ER oxycodone, methadone, morphine, hydromorphone or
fentanyl) that each participant used most often in the past 90 days (South Florida) or self-
reported to be their primary drug (SKIP). Because the highest potency prescription opioids
(hydromorphone, morphine, and fentanyl) were reported by few participants to be their
primary prescription opioid of abuse, these three medications were combined into a single
“high potency opioid” category. Buprenorphine and Tramadol were also reported by very
few participants (<2% of the total population in both studies), and accordingly, they have
been excluded from the analysis.
The diversion sources through which each participant obtained their primary prescription
opioid in the most recent 30 or 90 day period were then determined from the data base.
Except for one question in the SKIP survey which asked for the one primary means of
diversion, in all other cases participants were asked to report all sources for diverted
medication. Thus, the participants’ primary prescription opioid may have been obtained
through more than one source. In the analyses presented here, certain diversion sources were
combined or eliminated. For the SKIP and South Florida study, Internet purchases and
transportation from another country were very rare sources of diverted drugs (< 1% in both
studies) and were dropped from the analyses. Sharing/trading and friends/family members
were combined into one diversion category because of their similarity and frequent overlap.
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Theft, forged prescriptions and other illegal activities were also combined into a single
category since their frequency was quite low. The SKIP survey only asked whether a
doctor’s prescription was the source of drugs. Thus, types of physician sources were
collectively grouped into a category “medical practice,” along with use of an emergency
room physician. For the South Florida study, diversion sources related to the health care
system were more specifically delineated. Cases where the prescribing physician was most
likely unaware that their patients were misusing the drug in question (regular doctor and
doctor shopping) were combined into a new category called “legitimate medical sources.”
Sources related to the health care system where the medical professionals involved were
almost certainly aware that their patients were misusing the opioid medication (pharmacies
and script doctors (“pill mills”) were combined into a new category called illegitimate
medical sources.
Bivariate logistic regression models were developed to predict use of each diversion source
by demographics, by physical health status, by primary opioid, by injection drug use status,
by relative wealth (SKIP), by access to health insurance (South Florida) and by DSM-IV
drug dependence criteria (South Florida).
Results: The SKIP Population
Demographics
The mean age of the sample was 34.1 (SD 10.6; range 18–72). There were almost equal
numbers of males and females. The sample was overwhelmingly white (82.5%) with
extremely low yearly incomes: 70% earned less than $25,000 annually. Moderate to severe
pain was prevalent in 59.2% of the patients, most of whom used a doctor’s prescription as
their source of drugs (Table 1).
Illicit and Licit Drug Abuse
In addition to opioids, other licit and illicit drug use in the past 30 days was common. After
prescription opioids, the most commonly used licit drugs were benzodiazepines with over
53% of the population using them in the past 30 days.
General Patterns of Diversion
Figure 1 shows the percent of the SKIP sample whose diversion source was dealers, sharing,
medical practice and theft. The data are shown in two ways: patients were asked to either
report a primary diversion mechanism, or to list all diversion sources they utilized (single or
multiple options). Clearly, when limited to their primary means of diversion, dealers were
the single most common source of prescription opioids, being twice as common as any other
means of diversion. Next in importance were medical practice—i.e. prescriptions by a
doctor (25%) —and then sharing/trading (20%). Theft was very rare, chosen by less than 5%
of the sample. When patients were allowed to check all sources of diversion they had used,
dealers were again the overwhelming choice, but doctor’s prescriptions and sharing were the
next closest choices by narrow margins. Again, the frequency of overt criminal activity
remained quite low in this sample.
Gender, Age, Ethnicity, and Socioeconomic Status
Table 2 shows the odds ratios, 95% confidence intervals and p values for all predictors of
diversion, with statistically significant findings in boldface type. Women were significantly
less likely to use dealers to obtain prescription opioids than men, but significantly more
likely to use doctor’s prescription, sharing, and, marginally, theft. Age also determined
method of diversion. Young abusers 18–24 years of age were far more likely to use dealers
(OR=2.003) and theft (OR=1.333) as their sources of drug, whereas those 45 years of age or
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older were three times less likely to use a dealer (OR=0.333) and 30% less likely to share/
trade (OR=0.736), but far more likely to use a medical source (OR=2.298). In terms of
ethnicity, whites were significantly less likely to report sharing as a source than were non-
whites. We found that the poorest participants (<$ 10,000 annually) were more likely to use
dealers, sharing and theft as diversion sources when compared to “wealthier” (>$40,000)
participants. For medical practice sources, precisely the opposite pattern was observed, with
the “wealthier” much more likely to obtain opioids from a doctor’s prescription than their
poorer counterparts.
Role of Primary Drug and Route of Administration
As shown in Table 2, those who injected their primary drug in the last 30 days were much
more likely than non-injectors to use dealers and theft as sources of prescription opioids and
much less likely to use a doctor. The selection of a primary drug also influenced the method
of diversion. For example, those who used extended release oxycodone as their primary drug
(35% of the SKIP population) obtained the drug from a dealer much more frequently than
users of other opioids and much less frequently from a doctor. Conversely, users of the
second most common primary drug—hydrocodone—were more likely to use a doctor’s
prescription and less likely to use dealers to obtain this medication. Primary methadone
users were also more likely to use doctor’s prescriptions and less likely to report sharing/
trading and theft as sources. Finally, users of high potency opioids, were much less likely to
obtain these medications through a doctor’s prescription than those using other opioids.
The South Florida Study
Demographics
Demographic, health, and substance use characteristics of the sample are shown in Table 3.
The mean age was 34.6 years (SD 10.6; range 18–59); 56% of respondents were male. The
racial/ethnic makeup of the sample reflects the broad diversity of South Florida’s
population: 25.8% were African-American/African-Caribbean; 15.7% Hispanic/Latino,
53.6% white and 4.9% other race. Fewer than half (45.5%) of participants reported having
any type of health insurance, but a majority (57%) said that their physical health problems
limited their ability to carry out vigorous activities, and almost two-thirds (63.3%) reported
severe pain in the past 90 days.
Illicit and Licit Drug Abuse
Powder cocaine use was reported by 61.0% of respondents, and crack cocaine by 49.2%;
illicit substance use, including cocaine as one of the substances, was an eligibility
requirement for street users and MSM. Heroin use was reported by only 17.6% of the
sample; primary heroin users were not included in the sample analyzed for this paper
because of the problematic overlap/substitution with prescription opioids. Current (past 90
day) injection drug use was reported by 21.4% of the sample.
The most commonly reported primary prescription opioid of abuse was immediate release
oxycodone, reported by 58.1% of all respondents. Extended release oxycodone was the
second most common primary prescription opioid (18.2% of respondents). Hydrocodone
was the primary abused prescription opioid for 15.5% of respondents, and the remaining two
opioid categories, methadone and high potency opioids medications, were reported to be the
primary opioids for few respondents, at 5.5% and 2.8% of the sample respectively. DSM-
IVR criteria for substance dependence were met by 27.9% of respondents.
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General Patterns of Diversion
Sources through which respondents obtained their primary prescription opioid were diverse,
but majorities reported using dealers (66.6%) and sharing or trading with family or friends
(54.6%). Just 13.8% of respondents reported obtaining their abused opioids through
legitimate medical sources (by doctor shopping or from their regular doctor), likely without
the medical provider knowing their patient misused the medications. A somewhat lower
proportion (12.5%) of the sample obtained their primary opioid from medical sources who
most likely knew that the patient was abusing the drug sources (pharmacies or script
doctors). Theft was reported as a diversion source by 11.1% of respondents.
Dealers
The results of bivariate logistic regression models predicting each diversion source for
participants’ primary opioid are shown in Table 4. Study respondents who said they used
dealers to obtain their primary opioid in the past 90 days were younger, more likely (1.779
times) to be white, and less likely (0.653 times) to be African American than those who did
not access their diverted medications through dealers. Primary hydrocodone users were
about half (0.444 times) as likely to use dealers to obtain their primary drug compared to
respondents who reported other opioids as their primary drug. Those reporting current drug
injection were over three (3.537) times, and those meeting DSM-IVR criteria for drug
dependence about 50% (1.458 times), more likely to obtain their primary opioid from
dealers.
Sharing
Only one of the measures examined as a predictor of diversion methods was statistically
significant for sharing or trading medications to obtain abused opioids: those reporting
Hispanic ethnicity were about half (0.555 times) as likely to report this method as non-
Hispanics.
Medical Sources
Respondents who reported obtaining their primary opioid from legitimate medical sources
were more likely (1.733 times) to have health insurance, and also more likely (1.751 times)
to report physical health problems and about twice (1.998 times) as likely to report recent
severe pain than those who did not get their abused medications from legitimate medical
sources. Those who injected drugs and those whose primary opioid was hydrocodone were
also more likely to obtain their abused medications from legitimate medical sources.
Primary ER oxycodone abusers were about half (0.470 times) as likely to get their primary
opioid from legitimate medical sources compared to participants who reported other primary
opioids. Respondents who obtained their primary opioid from illegitimate medical sources
(pharmacies and script doctors) were about twice as likely to report physical health
limitations and recent severe pain as those who did not use those sources.
Theft
Study respondents who said they used theft to obtain their primary opioid in the past 90 days
were younger, more likely (1.850 times) to be white, and less likely (0.517 times) to be
African American than those who did not access their diverted medications through theft,
the same characteristics as those who obtained their diverted medications from dealers. Drug
injectors were about three times as likely to steal their primary opioid as those who did not
recently inject drugs. Respondents whose primary opioid was IR oxycodone were more
likely (1.803 times) to obtain their drugs by theft than those who reported other opioids as
their primary abused opioid.
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Discussion
In this paper we explored the factors that influence the diversion of prescription opioids in
two studies: first, a nationally-based self-administered brief survey of treatment patients
(SKIP); and, second, a highly focused and detailed interview based survey in a number of
distinct populations of drug users in South Florida. These studies complement one another
and overcome limitations in both, such as the often criticized use of self-administered
questionnaires, rather than direct interviews, and the presumed lack of generalizability in
focused regional analyses (Aquilino, 1994; Aquilino & LoSciuto, 1990; Hochstim, 1967;
Manchikanti et al., 2010; Monheit, 2010; Okamoto et al., 2002; Robling et al, 2010;
Ruetsch, 2010; Strassels, 2009; Tourangeau & Smith, 1996). Our results suggest very
comparable results between the two distinctly different studies, thus validating the use of
both paradigms in drug abuse related studies.
As mentioned above, there has been a surge in the non-therapeutic use of prescription
opioids in the past 15 years (Inciardi et al., 2009; Monheit, 2010; Manchikanti et al., 2010;
Ruetsch, 2010; Strassels, 2010; Zacny et al., 2003). Since it is rare for legitimate patients to
abuse their opioid medications, the appetite for these drugs is primarily driven by non-
patients who seek them for their mood-altering or other non-therapeutic effects. Thus, the
accessibility of these drugs to the abuser is the result of their diversion from legal sources to
the illicit market place. Previous research has suggested a variety of diversion mechanisms
(CASA, 2004; Inciardi, 2005; Inciardi & Surratt, 2005; Leiderman, 2006; NADDI [abed],
2005; Weathermon, 1999); however, there is limited systematic evidence to support each of
these diversion channels, and there are no empirical data on the magnitude of particular
types of diversion and the factors that influence the diversion method selected (Dart, 2009;
Dasgupta & Schnoll, 2009; Johanson et al., 2009; Liederman, 2009; McCormick, 2006;
Sapienza, 2006). The present studies provide the first empirical data on the scope and
magnitude of diversion among a nationally representative sample of dependent (DSM-IV)
misusers entering drug treatment programs and a diverse population of dependent and non-
dependent individuals in South Florida.
In general terms, the SKIP data indicate that dependent prescription opioid abusers used
dealers as their primary source (>50%) followed at some distance by sharing and doctor’s
prescriptions. However, when asked to list all methods of diversion in the past 30 days—
dealers, sharing, and doctor’s prescriptions were selected with almost equal frequency.
Surprisingly, despite wide-spread reports and speculation, particularly from the DEA and a
great deal of media coverage (GAO, 2003), SKIP respondents rarely resorted to theft, forged
prescriptions or other illegal activities to obtain their drugs of choice. These data are
consistent with the view that risk-aversiveness is a prominent trait of prescription opioid
abusers quite unlike that observed with users of illicit opioids, crack, methamphetamines
and other illicit drugs. This was true even among the South Florida sample, which included
many illicit drug abusers.
While the general conclusions outlined above apply to the overall population of prescription
opioid abusers, our studies indicate substantial differences in diversion by age, gender, route
of administration and the selection of a primary drug.
In terms of the likelihood of using various methods of diversion, it appears, as mentioned
above, that risk aversiveness may play a prominent role. For example, older people and non-
injectors avoided dealers and theft, but preferred physician practices as their source of drugs.
These data are consistent with many studies suggesting that younger age is associated with
higher levels of risk taking (Haase & Silbereisen, 2010).
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Both studies presented here also showed similar socioeconomic and health predictors of
abusers’ sources of diverted medications. Those with access to resources—health insurance
in the South Florida study, and higher income in the SKIP study—were more likely to
obtain abused opioid medications from medical system sources. Those with severe pain and
physical health problems were also more likely to go to physicians, legitimate or not, for
their opioid drugs.
The other major theme emerging from our studies is that the choice of a primary drug
strongly influences the method of diversion. Perhaps, the clearest examples of this are
evident with the two most commonly abused opioids in this country: OxyContin (35% of the
SKIP sample) and hydrocodone (26% of the sample). In both studies, for those for whom
OxyContin was their drug of choice, dealers were more likely to be reported (not quite
reaching the .05 level of significance in the South Florida study) and doctors were less likely
to be reported. Precisely the opposite pattern was observed for hydrocodone users in which
dealers were rarely used, but doctors were commonly used. While the factors underlying
these differences may be numerous, the most probable ones are cost, availability, and a
physician’s willingness to prescribe the medication. Hydrocodone products are the most
widely prescribed opioid analgesics in this country, outpacing oxycodone by more than 2 to
1. Thus, doctors are obviously willing to prescribe it and, even with a relatively small
percent of diversion from medical to non-medical channels, supplies are large in both the
licit and illicit market place. Thus, there may be little reason for users to resort to a dealer’s
“marked-up” prices when hydrocodone can be easily and safely obtained elsewhere,
particularly from a doctor or friends and family at relatively little cost.
The latter point may also explain the pattern of diversion for OxyContin users. Doctors have
grown wary of prescribing OxyContin given the media coverage of its abuse and overdose
deaths (Sproule, Brands, Li, & Catz-Biro, 2009). Perhaps more importantly, insurance
companies have become increasingly unwilling to pay for expensive OxyContin, as a brand
name with no currently available generic, when there are far cheaper opioid alternatives (e.g.
hydrocodone) and, increasingly, methadone. Thus, doctors may no longer be as reliable a
diversion source for OxyContin as they once were and, as a result the decline in its medical
use makes the drug less available from friends or families for sharing. As a consequence,
dealers may have become a more reliable outlet for OxyContin, which retains its popularity
as a “street drug” because it contains up to 10–15 times more active ingredient than IR
oxycodone or all hydrocodone products. Ironically, in our capitalistic system the great
demand for OxyContin has driven prices to extremely high levels (e.g., $ 1 per milligram)
making this drug far more expensive than heroin in most communities, generating a
dangerous anomaly not seen before in the opioid abuse field: Heroin has become a
secondary drug when the preferred drug—OxyContin—is unaffordable or in short supply
(Spiller, Bailey, Dart, & Spiller, 2010; Sproule et al., 2009).
As mentioned above, the reluctance of doctors to use the widely abused OxyContin and the
unwillingness of insurance companies to pay for it has had the unintended consequence of
increasing the use and abuse of methadone (Cai, Crane, Poneleit, & Paulozzi, 2010; Paulozzi
et al., 2009). Aside from making doctors the primary source of methadone for substance
abusers, this has led to a marked increase in the abuse of methadone, previously rarely
abused, and an unfortunate increase in fatal overdoses (Paulozzi et al., 2009; Braden et al.,
2010; Sale, Thielke, & Topolovec-Vranic, 2010). The latter is probably due to the lack of
knowledge of the pharmacology and toxicology by both users and doctors.
As mentioned above, the two studies described in this paper were undertaken to provide
complimentary empirical data on the methods of diversion used by prescription opioid users
entering treatment (SKIP) and in the broader spectrum of opioid misusers either in or out of
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treatment in the South Florida study. Thus, the later study assesses diversion in both
dependent and recreational users, whereas the SKIP study consists solely of only dependent
individuals. Interestingly, when examining only dependent individuals the two studies
yielded almost identical results: dealers were by far the primary mode of diversion. On the
other hand, non-dependent individuals tend to use dealers less frequently, apparently
preferring sharing, trading, and doctor’s prescriptions as sources of their drugs. In addition
to this important distinction, the complementary nature of the two studies validates that the
use of self-administered surveys produces results almost identical to those achieved with
direct interviews. While some prior investigations have suggested this to be the case, many
more investigators believe self-administered surveys are not credible (Aquilino, 1994;
Aquilino & LoSciuto, 1990; Hochstim, 1967; Okamoto et al., 2002; Robling et al., 2010;
Tourangeau & Smith, 1996), particularly with respect to drug abuse and misuse studies.
However, the latter conclusion has rarely been based on direct comparisons between the two
methodologies as has been done in the current studies. Thus, we believe our results indicate
that both self-administered and interview based studies produce valid data. Additionally,
focused studies in one city or region are often criticized for lack of generalizability to a
national sample (Aquilino, 1994; Aquilino&LoSciuto, 1990;Hochstim, 1967; Okamotoetal.,
2002; Robling et al., 2010; Tourangeau & Smith, 1996). Once again our results suggest that
this criticism may be overstated given the close correspondence between our results.
In conclusion, our data clearly indicate that the use of the term diversion to describe the
access of non-patients to prescribed medications is a misnomer since it is not a unitary
concept. Rather, there appears to be almost as many methods of “diversion” as there are
groups of people who misuse opioid medications. This information is important as we
consider prevention and intervention strategies for reigning in the national epidemic of
prescription drug abuse: a one size fits-all approach to limiting access through diversion will
clearly not address the illegal channeling of opioids from medical non-medical channels.
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Figure 1.
Sources of Primary Diverted Opioid-Opioid Dependent Treatment Clinics
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Table 1
Characteristics of Prescription Opioio-Dependent Treatment Clients (N=1983)
N %
Demographics
 Age (mean, SD) 34.1 (10.6)
 Age Groups:
  18–24 386 19.5
  25–34 790 39.8
  35–44 437 22.0
  45+ 370 18.7
 Male, gender 974 49.1
 Ethnicity:
  Hispanic 83 4.2
  African American/Caribbean 103 5.2
  White 1636 82.5
  Other/unknown 161 8.1
 Yearly Income:
  <10,000 930 47.7
  10,000–24,999 455 23.4
  25,000–39,999 326 16.7
  40,000 or more 237 12.2
Physical Health
 Moderate to Severe Pain—past 7 days 1154 59.2
Substance Use (past 30 days)
 Cocaine (powder) 585 30.2
 Crack cocaine 366 18.9
 Heroin 172 8.7
 Rx benzodiazepines 1033 53.4
Inject primary drug 459 25.3
Primary opioid used:
  Hydrocodone 516 26.0
  IR oxycodone 299 15.1
  ER oxycodone 699 35.2
  Methadone 207 10.4
  High potency (hydromorphone/fentanyl/morphine) 262 13.2
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Table 3
Characteristics of Prescription Opioid Abusers in South Florida (N=782)
N %
Demographics
 Age (mean, SD) 34.6(10.6)
 Male gender 443 56.6
 Ethnicity:
  Hispanic 123 15.7
  African American/Caribbean 202 25.8
  White 419 53.6
  Other 38 4.9
Physical Health
 Any health insurance 356 45.5
 Health currently limits activities 447 57.2
 Severe pain—past 90 days 494 63.3
Substance Use (past 90 days)
 Cocaine (powder) 477 61.0
 Crack cocaine 385 49.2
 Heroin 138 17.6
 Rx benzodiazepines 627 80.2
 Injection drug use 167 21.4
 Primary opioid used:
  Hydrocodone 121 15.5
  IR oxycodone 454 58.1
  ER oxycodone 142 18.2
  Methadone 43 5.5
  High potency (hydromorphone/fentanyl/morphine) 22 2.8
DSM-IV past year dependence 218 27.9
Source(s) of Diverted Primary Opioid
 Dealer 521 66.6
 Sharing/Trading 427 54.6
 Legitimate Medical Practice 108 13.8
 Illegitimate Medical Practice 98 12.5
 Theft 87 11.1
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